Preliminary analysis of one-year progression-free survival data from Phase 2 study of novel SST2 agonist paltusotine under investigation for carcinoid syndrome demonstrated potential anti-tumor ...

A novel combination therapy pairing a DNA-synthesis inhibitor with a targeted radiopharmaceutical may improve outcomes for patients with advanced neuroendocrine tumors, according to new clinical trial ...

The Nature Index tracks primary research articles from 178 applied, health, natural and social sciences journals, across many different publishers, chosen by an independent group of researchers. The ...

A novel approach for early cancer treatment known as radioligand therapy (RLT) has been shown to significantly reduce the risk of advanced neuroendocrine tumor progression and death, according to ...

Eftilagimod Alpha Plus Pembrolizumab in First-Line Metastatic Non–Small Cell Lung Cancer: Results From a PD-L1–Unselected Population in the TACTI-002 Study The mammalian target of rapamycin (mTOR) ...

The Neuroendocrine Tumor Research Foundation (NETRF), previously known as the Caring for Carcinoid Foundation (CFCF), is a nonprofit corporation organized under the laws of Massachusetts in order to ...

MIAMI, FLORIDA (April 30, 2024) – Newly updated guidelines on neuroendocrine tumors developed by an expert at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine ...

177Lu-edotreotide significantly extends median progression-free survival in GEP-NET patients compared to Afinitor, with 23.9 versus 14.1 months. Safety profile of 177Lu-edotreotide is favorable, with ...

Neuroendocrine tumours (NETs) encompass a heterogeneous group of neoplasms arising from hormone‐producing cells dispersed throughout the body, most commonly in the gastroenteropancreatic system and ...

DelveInsight's Neuroendocrine Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, emerging neuroendocrine prostate cancer drugs, market share ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Aman Chauhan, M.D., leader of the Neuroendocrine Tumor Program at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, and associate professor of medical ...